Internationally Renowned Lung Cancer Expert Comes To Ohio State

October 17, 2012

COLUMBUS, Ohio – Internationally renowned lung cancer expert Dr. David Carbone will be developing and leading a new thoracic oncology center at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). The thoracic oncology center will bring together physicians and scientists to develop new and targeted approaches to treating and curing lung cancer.

Carbone is an expert in the molecular genetics of lung tumors, which includes understanding the specific cells and genetic markers in each patient's lung cancer and developing treatments and drugs that target specific tumor cells. He comes to Ohio State from Vanderbilt University, where he was a professor of medicine and cancer biology and directed the experimental therapeutics program, and then the thoracic and head and neck cancer program, at the Vanderbilt-Ingram Cancer Center. In addition, he led the Thoracic Oncology Program at Vanderbilt.

His research interests, grant support and publications focus on lung cancer, specifically genetics, immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy.

"Ohio State's cancer program has some of the world's brightest minds in cancer biology, targeted therapies for specific cancers and cancer prevention," says Dr. Michael Caligiuri, director of the Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute. "And our cancer researchers work closely with our physicians, taking discoveries in the lab and translating them into targeted treatments for patients. David is truly a world leader, not just in his research on the cellular and molecular levels of lung cancer, but also in translational research, taking those discoveries from the bench to the bedside."

Caligiuri further explained that the translational research expertise Carbone brings to the new thoracic oncology center will benefit patients.

"His vision for integrating laboratory and clinical research with patient care will further our translational research efforts in lung cancer, and ultimately will improve the lives of lung cancer patients," Caligiuri said.

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer deaths in this nation. Lung cancer accounts for about 14 percent of all new cancers, and this year alone more than 226,000 men and women in the United States will be diagnosed, and 160,000 will die from the disease.

"As a lung cancer specialist, I'm determined to make a difference and to contribute to knowledge in the field by training other physicians, doing research and caring for patients," Carbone says. "By taking a team approach and combining research with optimal clinical care, we can improve the lives of lung cancer patients."

Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined, Carbone said.
As a cancer survivor himself, Carbone shares a special empathy with his patients. In 1999, he was successfully treated for mediastinal large cell lymphoma. His therapy included removing part of his left lung and receiving chemotherapy and chest radiation – similar treatments he often recommends for his lung cancer patients.

He has authored more than 200 peer-reviewed publications, book chapters and review articles and has served on several National Cancer Institute (NCI) grant review panels. He also serves as chairs of the Scientific Advisory Boards for the Addario Lung Cancer Medical Institute; the Lung Cancer Foundation of America and Lungevity.

Carbone earned a medical degree and a doctorate degree in molecular biology and genetics from Johns Hopkins University. He then did an internal medicine internship and residency at Johns Hopkins and completed a medical oncology fellowship at the NCI. He began his career at the University of Texas Southwestern Medical Center, and remained there for five years before joining the faculty at Vanderbilt in 1996.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Contact: Eileen Scahill, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Drug Harnesses Immune System To Combat Most Common Form of Lung Cancer

Recently approved immunotherapy drugs are offering patients – and their oncologists – new hope for extending survival of people with advanced non-small cell lung cancer (NSCLC).

Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in...

One Day to Help Create More Healthy — And Cancer-Free — Tomorrows

Through the generous support of Don and Angie Ward, all donations made to Ohio State's cancer program today (Nov. 24) through Giving Tuesday (Dec. 1), will be matched, 100 percent, up to $50,000.